[A case of complete remission from acute unclassified leukemia achieved by using a prodrug of ara C, stearyl-ara-CMP (YNK01)].
YNK01 (a daily oral dose of 450 mg) was administered for 22 days to a 58-year-old-female with Ph1-positive acute unclassified leukemia. Leukemia cells were negative for peroxidase and esterase, but were positive for CD19, CD13, CD34, CD9, HAL-DR, CD25, and TdT. Complete remission was obtained and continued for at least a month. The main side effects noted were diarrhea and melena. The administration of YNK01 resulted in plasma ara C levels that ranged between 15.4 to 23.0 ng/ml, which appear to be nearly equivalent to dose achieved during continuous IV infusion of a low dose (20 mg/m2/day) of ara C.
Nishikawa
M
M
2nd Dept. of Int. Med. Mie Univ. School of Med.
Morita
K
K
Komada
F
F
Uemura
Y
Y
Kageyama
S
S
Minami
N
N
Deguchi
K
K
Shirakawa
S
S
D000208:Acute Disease; D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001088:Arabinonucleotides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003561:Cytarabine / Q000097:blood; D003568:Cytidine Monophosphate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D008875:Middle Aged; D011355:Prodrugs; D012074:Remission Induction
D000970:Antineoplastic Agents; D001088:Arabinonucleotides; D011355:Prodrugs; D003561:Cytarabine; C061162:1-arabinofuranosylcytosine-5'-stearylphosphate; D003568:Cytidine Monophosphate